NuCana (NCNA) shares were up 200% pre-bell Monday after the company said that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
Dermata Therapeutics (DRMA) stock was over 64% higher following a 6.8% rise in the previous session.
Exicure (XCUR) shares were up 43%, adding to Friday's 5.3% increase.
Agape ATP (ATPC) stock was 26% higher, extending Friday's rally.
Nuvalent (NUVL) shares were up nearly 16% after Friday's 7.1% rise.
Price: 7.6200, Change: +5.08, Percent Change: +200.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。